← Back to Clinical Trials
Recruiting NCT07250100

NCT07250100 The Role of Microbiota in Pancreatic Cancer and Precursor Lesions

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07250100
Status Recruiting
Phase
Sponsor Herlev Hospital
Condition Pancreatic Cancer
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2025-11-01
Primary Completion 2030-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
observational study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2025-11-01 with a primary completion date of 2030-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective observational study aiming to investigate the microbiome in patients suspected of having pancreatic cancer. The purpose is to enhance diagnostic accuracy by developing screening protocols for high-risk individuals, identifying specific microbial biomarkers, and improving prognostic criteria to optimize treatment response. Participants will be asked to complete a questionnaire, provide oral and fecal swabs, and-if clinically indicated-1-2 pancreatic biopsies will be collected.

Eligibility Criteria

Inclusion Criteria: * Patients with a suspected lesion (solid/cystic) in the pancreas undergoing diagnostic or therapeutic endoscopic procedure * Age of 18 years or above * Signed informed consent form Exclusion Criteria: * Contraindications for endoscopic or surgical procedure, such as uncorrected coagulopathy

Contact & Investigator

Central Contact

Bojan Kovacevic, ph.d., MD

✉ bojan.kovacevic@regionh.dk

📞 0045 3868 6312

Frequently Asked Questions

Who can join the NCT07250100 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07250100 currently recruiting?

Yes, NCT07250100 is actively recruiting participants. Contact the research team at bojan.kovacevic@regionh.dk for enrollment information.

Where is the NCT07250100 trial being conducted?

This trial is being conducted at Herlev, Denmark.

Who is sponsoring the NCT07250100 clinical trial?

NCT07250100 is sponsored by Herlev Hospital. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology